american society of anesthesiologists glp 1 Glucagon-Like Peptide-1 Receptor Agonists in Perioperative Care Aspiration risk tops anesthesiologists' concerns

Patients who fail to respond adequately to semaglutide often respond better to tirzepatide, not because of dose differences but because the dual mechanism addresses different pathways

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Discussion with Vida-Flo Medical Personnel: Each patient has a one-on-one discussion with our medical staff

Guiramand, J

Tesamorelin has been studied at a daily subcutaneous dose of 2 mg, which corresponds to the approved dosing regimen